Zealand Pharma stock declined following a high-profile analyst reassessment that highlighted an absence of imminent value-driving catalysts and renewed questions about the clinical profile of its lead candidate. Jefferies moved the Danish biotech from a Buy rating to Hold and reduced its price target to DKK 320 from DKK 505 - a cut of roughly 37% - stating that it does not expect near-term value-crystallising events in the second half of 2026.
The firm also adjusted its internal modelling for survodutide, Zealand’s glucagon/GLP-1 dual agonist developed with Boehringer Ingelheim, lowering the probability of success to 40% from 60%. Jefferies cited ongoing concerns about the drug’s tolerability and clinical profile after Phase III data were presented at the American Diabetes Association meeting in June.
Those views echo recent analyst revisions across the sell side. Wolfe Research last month removed its Outperform rating for the survodutide franchise on tolerability grounds, pointing specifically to a placebo-adjusted patient discontinuation rate that was far higher than the rates reported for competing therapies from Novo Nordisk and Eli Lilly. Jefferies and other firms, including UBS, have suggested that a meaningful inflection point for the stock is unlikely before 2027.
With near-term upside seen as limited by several sell-side shops, market attention has shifted toward Zealand’s petrelintide program, an amylin analog being advanced into Phase 3 trials in partnership with Roche. Multiple analysts have indicated that progress from petrelintide will be a central element of the company’s narrative until clearer data emerge from survodutide or other programs.
On the trading floor, the downgrade was the dominant company-specific driver of price action in the absence of any Zealand Pharma earnings releases or corporate announcements on the date in question. The stock fell 2.0% on the session after Jefferies’ move. A real-time quote in the report showed the share price at DKK 275.70, down DKK 5.20 or -1.85% at 07:05:34, reflecting intraday fluctuations.
Macro and market context also contributed to the negative tone. Copenhagen’s OMXC25 benchmark traded in negative territory and underperformed the stock’s sector peers, while U.S. equity markets were also softer, with the S&P 500 and Nasdaq both trading lower. These broader risk-off conditions compounded investor caution toward the biotech name.
Taken together, the prominent analyst downgrade, the materially lower price target, and unresolved concerns stemming from survodutide’s tolerability data pushed Zealand Pharma shares nearer to their 52-week low of DKK 233.5 than to the 52-week high of DKK 556. The market reaction underscores investor wariness while the company awaits additional clinical readouts and clearer catalysts.
Summary
Jefferies downgraded Zealand Pharma to Hold and cut its price target to DKK 320 from DKK 505, lowering the probability of success for survodutide to 40% from 60%. The downgrade, compounded by earlier analyst concerns over tolerability, left the stock down roughly 2.0% amid weak broader markets and no company-specific announcements.
- Key points:
- Jefferies lowered its rating to Hold and reduced its price target by roughly 37% to DKK 320.
- Probability of success for survodutide was cut to 40% from 60% following Phase III data presented at the American Diabetes Association meeting in June.
- Petrelintide, an amylin analog in Phase 3 with Roche, is now a central near-term focus for the company’s clinical narrative.
- Risks and uncertainties:
- Tolerability concerns for survodutide, including a higher placebo-adjusted patient discontinuation rate versus rivals, present a clinical and commercial risk for the biotech sector.
- Analyst expectations that a material inflection point is unlikely before 2027 create timing uncertainty for investors in Zealand and can influence equity-market exposure to biotech and healthcare names.
- Broader market weakness, as seen in the OMXC25 and U.S. indices, may amplify downward pressure on the stock absent company-specific positive news.